Glykos Finland

Glykos is a Finnish biotech company specializing in next-generation antibody-drug conjugates (ADCs) for oncology. Its core innovation is a proprietary platform featuring hydrophilic linkers and novel payloads (including auristatin, anthracyclin, and exatecan classes) designed to significantly widen the therapeutic window. The company is in late preclinical development with a lead candidate targeting CD33 for AML and MM, and has secured a major collaboration with Orion Corporation, signaling strong validation of its technology. Glykos operates as a private, preclinical-stage firm combining internal pipeline development with platform licensing and service offerings.

Proprietary ADC platform featuring hydrophilic linkers for improved PK/tolerability and novel cytotoxic payloads (auristatin MMAU, anthracyclin, exatecan classes) enabling site-specific conjugation and a widened therapeutic window.

Glykos competes in the crowded and innovative ADC technology space against companies like ImmunoGen, Seagen (Pfizer), Mersana Therapeutics, Synaffix (Lonza), and others developing novel linkers, payloads, and conjugation methods. Its differentiation hinges on preclinical data demonstrating a superior therapeutic index for its hydrophilic linker and novel payload combinations.